3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
64
Neoplasm Metastasis
14
Brain Neoplasms
10
Neoplasms
9
Endometrial Neoplasms
8
Prostatic Neoplasms
7
Glioblastoma
7
Ovarian Neoplasms
6
Triple Negative Breast Neoplasms
5
Glioma
5
Sarcoma
3
Recurrence
3
Neoplasms by Site
3
Meningioma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Osteosarcoma
2
Liposarcoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Interventions
Cyclophosphamide
62
Rituximab
47
fludarabine
35
fludarabine phosphate
27
obinutuzumab
17
Mycophenolic Acid
16
ibrutinib
15
Whole-Body Irradiation
15
Lenalidomide
15
Specimen Handling
14
Prednisone
14
venetoclax
13
pirtobrutinib
13
Etoposide
13
Doxorubicin
13
pembrolizumab
12
Tacrolimus
12
Magnetic Resonance Spectroscopy
11
Granulocyte Colony-Stimulating Factor
11
Filgrastim
11
Biopsy
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
X-Rays
9
Bendamustine Hydrochloride
9
polatuzumab vedotin
8
glofitamab
8
acalabrutinib
8
Immunotherapy, Adoptive
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
abemaciclib
×
1 year
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled